Craft

Biocon

Stock Price

₹363.6

2024-09-18

Market Capitalization

₹423.7 B

2024-09-18

Revenue

₹142 B

FY, 2024

Biocon Summary

Company Summary

Overview
Biocon is a global biopharmaceutical company. It manufactures biologics, biosimilar insulins, and antibodies. The company focuses on the areas of diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology, and inflammatory diseases. It is also involved in the integrated discovery, development, and manufacturing services for small and large molecules, antibody-drug conjugates, and oligonucleotides.
Type
Public
Status
Active
Founded
1978
HQ
Bengaluru, IN | view all locations
Website
https://www.biocon.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Kiran Mazumdar Shaw

    Kiran Mazumdar Shaw, Executive Chairperson

  • Jonathan Hunt

    Jonathan Hunt, CEO & Managing Director, Syngene International

  • Shreehas P Tambe

    Shreehas P Tambe, Deputy Chief Executive Officer, Biocon Biologics

  • Daniel M. Bradbury

    Daniel M. Bradbury, Independent and Non-Executive Director

LocationsView all

12 locations detected

  • Bengaluru, KA HQ

    India

    20th KM, Hosur Road, Electronic City

  • Cambridge, MA

    United States

    245 Main St 2nd floor

  • Bengaluru, KA

    India

    Biocon House, Semicon Park, Electronics City, Phase – II, Hosur Road

  • Hyderabad, TG

    India

  • Visakhapatnam, AP

    India

  • Dublin, D

    Ireland

    9 Clare St

and 6 others

Biocon Financials

Summary Financials

Revenue (Q1, 2025)
₹33.8B
Gross profit (Q1, 2025)
₹34.2B
Net income (Q1, 2025)
₹8.6B
Cash (FY, 2024)
₹22.6B
EBIT (Q1, 2025)
₹13.8B
Enterprise value
$580.2B

Footer menu